{
    "clinical_study": {
        "@rank": "36770", 
        "arm_group": [
            {
                "arm_group_label": "Post-Transfection F17", 
                "arm_group_type": "Experimental", 
                "description": "Live attenuated tetravalent dengue (DEN) vaccine"
            }, 
            {
                "arm_group_label": "JE", 
                "arm_group_type": "Experimental", 
                "description": "Japanese encephalitis virus"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out more about the two doses of dengue vaccine, over a\n      five year period, that the children received in the Dengue-003 study and to study a third\n      dose of dengue that will be given to the children\n\n        -  Do children still have dengue antibodies intended to provide protection against dengue\n           infection one year after the two doses of vaccine given in study Dengue-003?\n\n        -  Were there any major medical problems that appeared as dengue-like symptoms during the\n           one year after vaccinations?\n\n        -  Will a third dose of dengue help to further stimulate the part of the immune system\n           intended to help protect against dengue infection?\n\n        -  Is a third dose as safe as the first two doses?\n\n        -  Are the local reactions to a third dose of the vaccine similar to what your child\n           experienced after the first two doses?"
        }, 
        "brief_title": "A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Dengue", 
        "condition_browse": {
            "mesh_term": "Dengue"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who received two doses of DEN vaccine in the Dengue-003 study and whose\n             parents signed an informed consent form were eligible for participation in the five\n             year follow-up study\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "9 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00318916", 
            "nct_id": "NCT01843621", 
            "org_study_id": "A-13227", 
            "secondary_id": [
                "GSK 103795", 
                "WRAIR 1159"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Post-Transfection F17", 
                "intervention_name": "F 17", 
                "intervention_type": "Biological", 
                "other_name": "Live attenuated tetravalent dengue (DEN) vaccine"
            }, 
            {
                "arm_group_label": "JE", 
                "intervention_name": "Japanese encephalitis virus", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Dengue, Vaccine, Thailand", 
        "lastchanged_date": "April 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phayathai", 
                    "country": "Thailand", 
                    "state": "Bangkok", 
                    "zip": "10400"
                }, 
                "name": "Department of Pediatrics, Phramongkutklao Hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 (\"A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children\") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series", 
        "overall_official": [
            {
                "affiliation": "Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand", 
                "last_name": "Sriluck Simasathien, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Armed Forces Research Institute of Medical Sciences (AFRIMS),  Bangkok, Thailand", 
                "last_name": "Robert Gibbons, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Thailand: Ethical Review Committee, Royal Thai Army Medical Department", 
                "Thailand: The Ethical Review Committee for Research in Human Subjects. Ministry of Public Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Neutralizing antibodies as measured by plaque reduction neutralization test (seropositivity rates and geometric mean titers [GMTs] to each dengue virus serotype, 30 days after the DEN vaccine booster dose", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after the DEN vaccine booster dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of solicited adverse events (AEs) within 21 days follow-up after the DEN  vaccine dose", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Occurrence of unsolicited non-serious AEs within 31 days (Day 0-30) after the DEN vaccine dose", 
                "safety_issue": "Yes", 
                "time_frame": "31 days"
            }, 
            {
                "measure": "Occurence of serious adverse events (SAE) within 31 days (Day 0-30) after the DEN dose", 
                "safety_issue": "Yes", 
                "time_frame": "31 days"
            }, 
            {
                "measure": "Occurence of abnormal findings at dengue physical examination after each vaccine dose", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Biochemistry and hematology parameters at Visit 1 (Day 0, year 1 post dose 2), Visit 3 (Day 10), Visit 5 (Month 1) and Visit 6 (Year 2)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "To assess the immunogenicity of a booster dose of dengue vaccine administered approximately one year following the second dose", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Tetravalent neutralizing antibody, 30 days after the DEN vaccine booster dose", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Neutralizing antibodies to each dengue virus serotype, before the DEN vaccine booster dose at Visit 1 (Day 0, Year 1 post Dose 2", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "measure": "Presence of dengue viremia 10 days after the dengue vaccine dose", 
                "safety_issue": "Yes", 
                "time_frame": "10 days"
            }, 
            {
                "measure": "Tetravalent neutralizing antibody and neutralizing antibodies to each dengue virus serotype one and two years after the booster dose", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Neutralizing antibody titers to Japanese encephalitis virus at visit 1 (Day, 0 ,Year 1 post Dose 2), visit 5 (Month 1) and visit 6 ( Year 2)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Flavivirus infection in terms of dengue immunoglobulin M and immunoglobulin G        per subject (ATP cohort for immunogenicity)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "February 2005", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}